Zicam Inventor Swindled Investors in Lucille Ball Scam, Gambled Funds at Las Vegas Casinos

A federal grand jury has indicted the inventor of cold remedy Zicam on fraud charges. He’s accused of bilking investors in a sham TV production company which he claimed had links to the late Lucille Ball.

Desilu
Lucille Ball and Desi Arnaz, above, formed Desilu Productions, which was hugely successful in its day. It was not affiliated with Desilu Studios, a shell company controlled by Zicam inventor Charles Henlsey. (Image: The List)

Charles Hensley, of Redondo Beach, Calif., used at least $331,000 of almost $600,000 extracted from 21 investors for personal expenses. These included lavish trips to unnamed Las Vegas casinos and payments to pawn shops, according to the indictment.

Hensley claimed he had made millions from Zicam. He did coinvent the product in the mid-1990s. But he was broke when he began canvassing for investment in his shell production company, Desilu Studios Inc (DSI), in August 2017.

He borrowed the name from Desilu Productions Inc., the company formed by Ball and her husband, Desi Arnaz, as a portmanteau of their first names. Desilu Productions was once the second-biggest production company in the US, creating classic television shows like I Love Lucy, Star Trek, and Mission Impossible before its demise in 1968.

Borrowed Name

At that time, Hensley had been “repeatedly bouncing checks and overdrawing bank accounts to get cash and pay expenses,” according to the indictment.

Hensley “falsely and misleadingly represented that he was affiliated with the real Desilu and making new content using the Desilu name,” reads the indictment.

He further told investors he was backing the company with his non-existent fortune from Zicam. DSI company was worth $11 billion, he claimed.

Hensley also pushed a phony pharmaceutical company, “Migranade,” which he said was valued at $50 million.

Phony IPO

Meanwhile, Hensley told investors that Desilu Productions was about to go public and that its stock was worth more than its face value, which would increase significantly after the imminent IPO.

DSI had few to no assets, no CFO, accountant, or auditor, no financial statements or any of the other requirements for an IPO, and the stock was not worth what was represented,” the indictment read.

Hensley obtained a trademark on the Desilu name from the US Patent Office in 2018. That year, he sued CBS Studios for the exclusive use of the mark. He subsequently withdrew the case and was countersued by CBS, which had used it continually for decades in its television programming.

Hensley has been charged with 11 counts of wire fraud and one count of aggravated identity theft, according to the US attorney’s office for the Central District of California. He faces up to 20 years in prison if convicted.

Philip Conneller
Philip Conneller Senior Reporter

In Philip Conneller’s eight years with Casino.org, he has covered the gaming industry from Las Vegas to Macau and everything in between. He currently focuses his coverage on gaming law, white-collar crime, global money laundering, tribal gaming, politics, and regulation.

Philip was the original features editor for poker’s Bluff Magazine and editor for Bluff Europe, which he helped launch. His writing has also been featured in ESPN, Forbes, Time Out, The Sun, and The Daily Star, as well as iGaming Business, eGaming Review, and numerous other industry news and tech websites.

His news stories for Casino.org/news have been linked by The Washington Post, The Daily Mail, People Magazine, and Jimmy Fallon's Tonight Show, among many others.

Philip once won $20,000 with 7-2 off-suit. He has been reprimanded for unwittingly playing Elton John’s piano on two separate occasions on both sides of the Atlantic.

He became a writer because he is a lousy pianist.

Philip lives outside London with his wife and children, where he spends his time agonizing about Arsenal FC.

Contact Philip at philip.conneller@casino.org.

Comments icon

Conversation (0)

+ Add a comment

Be the first to comment on this article.

Write a comment

Your email address will not be published.